Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BBIOthis companyBridgeBio Pharma, Inc.	$77.98	-20.18×	-7.27×	30.05×	-25.49×	-270.8%	94.4%	-113.3%	-145.3%	35.1%	-108.5%	-3.0%	-1.31×	-3.19×	-10.72×	2.62×	0.0%	2	-0.06	2	C
ALNYAlnylam Pharmaceuticals, Inc.	$156.72	166.38×	66.01×	14.03×	81.9×	-1049.5%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.7	4	A-
BMRNBioMarin Pharmaceutical Inc.	$57.26	32.65×	1.87×	3.54×	18.73×	-86.9%	77.1%	16.6%	10.8%	5.7%	5.6%	6.4%	0.11×	-1.17×	48.95×	5.21×	0.0%	2	1.87	2	C+
DNLIDenali Therapeutics Inc.	$20.49	-5.56×	2.86×	0×	-5.48×	-95.3%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-14.6%	0.04×	0.34×	0×	9.16×	0.0%	2	2.98	1	C-
IONSIonis Pharmaceuticals, Inc.	$31.00	-33.24×	25.88×	13.41×	-52.41×	-377.0%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	3	0.08	1	D+
MAZEMaze Therapeutics, Inc.	$35.28	-13.58×	5.02×	0×	-12.54×	-89.0%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	2	12.28	2	C
Peer median	—	-5.56×	5.02×	3.54×	-5.48×	-95.3%	77.1%	0.0%	0.0%	-36.9%	-12.0%	-2.5%	0.11×	-0.6×	0×	5.21×	0.0%	2	2.98	2	—